jcm-logo

Journal Browser

Journal Browser

Research and Applications in Clinical Pharmacy Based on Pharmacokinetics and Pharmacogenetics

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 587

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacy, Consorci Hospitalari de Vic, 08500 Barcelona, Spain
Interests: pharmacokinetics; pharmacogenomics; pharmacoeconomis; therapeutic drug monitoring
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of clinical pharmacy has evolved significantly in recent years, with pharmacokinetics and pharmacogenetics playing a central role in optimizing therapeutic outcomes for patients. Pharmacokinetics and pharmacogenetics provide critical insights that allow healthcare professionals to tailor treatments to individual patient needs. This Special Issue on “Research and Applications in Clinical Pharmacy Based on Pharmacokinetics and Pharmacogenetics” will bring together pioneering research and practical applications, highlighting the growing importance of pharmacokinetics and pharmacogenetics data in advancing personalized medicine. As the healthcare landscape becomes increasingly complex, this focus area will offer immense value to clinicians, pharmacists, and researchers who are dedicated to improving patient care.

The Special Issue will explore a range of themes at the intersection of clinical pharmacy, pharmacokinetics, and pharmacogenetics. Key topics of interest include the integration of pharmacokinetics and pharmacogenetics modeling into drug therapy management, emerging trends in drug monitoring, dosage adjustments, and new insights into drug–drug and gene–drug interactions. Additionally, this Special Issue will address the challenges faced by healthcare providers in translating pharmacokinetics and pharmacogenetics research into clinical practice, with a focus on achieving optimal therapeutic efficacy and safety across diverse patient populations.

The primary objective of this Special Issue is to disseminate cutting-edge research that bridges the gap between theory and clinical application in pharmacokinetics and pharmacogenetics. By highlighting innovative approaches to drug therapy management, we aim to enhance the ability of healthcare professionals to make informed decisions based on pharmacokinetics and pharmacogenetics data. We hope that this compilation will inspire new research collaborations and prompt discussions on the importance of personalized approaches to drug dosing in clinical settings. The ultimate goal is to foster advances that will improve patient outcomes and the precision of drug therapy.

The contributions included in this Special Issue will represent the forefront of clinical pharmacy research. Readers will find studies that provide novel insights into the pharmacokinetics and pharmacogenetics of both established and emerging therapeutics. These articles will offer practical recommendations for optimizing drug therapy based on patient-specific variables such as age, genetic factors, and co-existing medical conditions. This Special Issue will also feature research on the application of pharmacokinetics and pharmacogenetics in specific populations, including pediatric, geriatric, and critically ill patients, further expanding the relevance of these fields in everyday clinical practice.

We encourage healthcare professionals, researchers, and clinicians to engage with this Special Issue and explore its valuable contributions to the field of clinical pharmacy. By delving into these articles, readers will gain a deeper understanding of the applications of pharmacokinetics and pharmacogenetics in clinical settings. Moreover, we invite individuals to contribute their own research and insights, further enriching this growing area of study and advancing the conversation around individualized drug therapy.

In conclusion, this Special Issue will offer a significant opportunity to advance both knowledge and practice within the field of clinical pharmacy. By highlighting the critical role of pharmacokinetics and pharmacogenetics, it will underscore the importance of personalized medicine in improving patient care. We are confident that the insights presented here will serve as a valuable resource for practitioners and researchers alike, and we hope that this Special Issue will inspire further innovation in pharmacokinetics and pharmacogenetics and their application in clinical practice.

Dr. Marta Miarons
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • clinical pharmacy
  • personalized medicine
  • drug therapy management
  • therapeutic drug monitoring

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 981 KiB  
Article
The Pharmacokinetics of Saliva and Plasma N-Oxides Following a Single Administration of a Plant-Based Bioequivalent Inorganic Nitrate Oral Supplement in an Open-Label, Phase 1, Single-Arm Study
by Macy E. Stahl, Emily E. Grammer, Jason D. Allen and Arthur Weltman
J. Clin. Med. 2025, 14(13), 4581; https://doi.org/10.3390/jcm14134581 - 27 Jun 2025
Viewed by 278
Abstract
Background/Objective: Hypertension and other modifiable risk factors for cardiovascular disease are characterized by a dysfunctional vascular endothelium and decreased nitric oxide (NO) bioavailability. The oral supplementation of inorganic nitrate (NO3) has been shown to increase the salivary and plasma nitrite [...] Read more.
Background/Objective: Hypertension and other modifiable risk factors for cardiovascular disease are characterized by a dysfunctional vascular endothelium and decreased nitric oxide (NO) bioavailability. The oral supplementation of inorganic nitrate (NO3) has been shown to increase the salivary and plasma nitrite (NO2), a precursor to NO, though there may be significant variation in the pharmacokinetics of this process between different supplements. The purpose of this open-label, phase 1, single-arm study was to investigate the pharmacokinetic profile of the plasma and salivary NO3 and NO2 concentrations following the administration of a single serving of a plant-based bioequivalent inorganic nitrate oral supplement (“Berkeley Life Nitric Oxide Foundation Capsules”, Chicago, IL, USA). Methods: Nine males and three females (age: 33 ± 15 years; BP: 129 ± 6 mmHg; BMI: 27.58 ± 4.27 kg/m2) participated in the protocol. Following the baseline collection of saliva and plasma samples, the participants consumed 314 mg (two capsules) of the supplement. Saliva and plasma samples were collected at 2 h, 4 h, 8 h, and 24 h post consumption. Results: The peak salivary NO3 (13,326.12 ± 4926.60 µM), salivary NO2 (1375.27 ± 679.28 µM), plasma NO3 (498.37 ± 168.89 µM), and plasma NO2 (231.66 ± 97.26 nM) were observed at 2 h post-supplementation (p < 0.01 vs. the baseline). The concentrations of the salivary and plasma NO2 remained elevated at 8 h after administration (220% and 50% above the baseline, respectively), and the concentrations of the salivary and plasma NO3 remained elevated at 24 h after administration (22% and 50% above the baseline, respectively). Conclusions: These data suggest that a single serving of “Berkeley Life Nitric Oxide Foundation Capsules” taken once to twice per day is a viable strategy to provide sustained salivary and plasma NO3 and NO2 availability over 24 h and therefore may provide a viable approach for long-term blood pressure maintenance. Full article
Show Figures

Figure 1

Back to TopTop